Focus on vitamin D therapy in chronic kidney disease

Journal of Nephrology

Volumn 20, Issue 5, 2007, Pages 511-514

  Tentori, Francesca ^a  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; CALCITRIOL; CALCIUM; CALCIUM SENSING RECEPTOR; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; RENIN; VASCULOTROPIN; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; VITAMIN D;

APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; DRUG PULSE THERAPY; HEMODIALYSIS; HOSPITALIZATION; HUMAN; MORTALITY; PRACTICE GUIDELINE; PROTEIN EXPRESSION; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; SURVIVAL RATE; TREATMENT OUTCOME; BLOOD; BONE REMODELING; CHRONIC KIDNEY FAILURE; DRUG EFFECT; NOTE; PATHOPHYSIOLOGY; RENAL OSTEODYSTROPHY; RENAL REPLACEMENT THERAPY; SYNDROME;

BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIUM; HUMANS; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY; SYNDROME; TREATMENT OUTCOME; VITAMIN D;

EID: 38149089371     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Reichel H, Deibert B, Schmidt-Gayk H, Ritz E. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991; 6: 162-9.
2. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-53.
3. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-83.
4. Qunibi WY, Nolan CA, Ayus JC. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int Suppl 2002; 82: 73-80.
5. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-8.
6. London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Metivier F. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-20.
7. Krasniak A, Drozdz M, Pesowicz M, Chmiel G, Michalek M, Szumilak D, Podolec P, Klimeczek P, Konieczynska M, Wicher-Muniak E, Tracz W, Khoa TN, Souberbielle JC, Drueke TB, Sulowicz W. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant 2007; 22: 515-21.
8. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-18.
9. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-7.
10. Eknoyan G, Gyorkey F, Dichoso C, Gyorkey P. Nephropathy in patients with drug addiction: evolution of pathological and clinical features. Virchows Arch A Pathol Anat Histol 1975; 365: 1-13.
11. Martin KJ, Gonzalez EA, Gellens ME, Hamm LL, Abboud H, Lindberg J. Therapy of secondary hyperparathyroidism with 19-nor-1alpha, 25-dihydroxyvitamin D2. Am J Kidney Dis 1998; 32 (Suppl 2): S61-6.
12. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (Suppl 3): S1-202.
13. Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso AS. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 2001; 60: 2109-17.
14. Brown AJ, Zhong M, Finch J, Ritter C, McCracken R, Morrissey J, Slatopolsky E. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 1996; 270 (3 Pt 2): F454-60.
15. Tokuda N, Kano M, Meiri H, Nomoto K, Naito S. Calcitriol therapy modulates the cellular immune responses in hemodialysis patients. Am J Nephrol 2000; 20: 129-37.
16. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001; 15: 2579-85.
17. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-38.
18. Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler HP. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 1995; 55: 2822-30.
19. Morimoto S, Imanaka S, Koh E, Shiraishi T, Nabata T, Kitano S, Miyashita Y, Nishii Y, Ogihara T. Comparison of the inhibitions of proliferation of normal and psoriatic fibroblasts by 1 alpha, 25-dihydroxyvitamin D3 and synthetic analogues of vitamin D3 with an oxygen atom in their side chain. Biochem Int 1989; 19: 1143-9.
20. Yamamoto T, Kozawa O, Tanabe K, Akamatsu S, Matsuno H, Dohi S, Hirose H, Uematsu T. 1,25-dihydroxyvitamin D3 stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of p38 mitogen-activated protein kinase. Arch Biochem Biophys 2002; 398: 1-6.
21. Tangpricha V, Flanagan JN, Whitlatch LW, Tseng CC, Chen TC, Holt PR, Lipkin MS, Holick MF. 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet 2001; 357: 1673-4.
22. Zaloga GP, Chernow B. The multifactorial basis for hypocalcemia during sepsis: studies of the parathyroid hormone-vitamin D axis. Ann Intern Med 1987; 107: 36-41.
23. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-84.
24. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-25.
25. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-65.
26. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-80.
27. Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004; 19: 1174-81.
28. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-56.